Depressive symptoms frequently afflict individuals with Parkinson’s disease (PD). The current study was consequently conducted to determine the efficacy of low-dose intravenous esketamine in managing postoperative depressive symptoms, thereby exploring its potential mechanisms of action in PD patients subjected to non-intracranial surgery. In this randomized, double-blind, placebo-controlled...
Background: Depression is a common complication of Parkinson disease (PD). This study investigated whether a single dose of esketamine could alleviate depressive symptoms in an MPTP mouse model by activating G protein-coupled receptor 109 A (GPR109A) and reducing neuroinflammation. Methods: Adult male C57BL/6 J mice (8 weeks, 25–30 g) were allocated into three groups: saline,...